Programme 2020
Nordic Precision Medicine Forum
16-17 March 2020, Stockholm

  Denotes a link to a live speaker's bio page.

Scroll down for the full agenda or download the programme in PDF format.
For any enquiries about speaking opportunities or if you have an interest in hosting one of our workshops please email Amanda Rafferty

Nordic AI Medicine and Healthcare Forum Agenda HERE

16-17 March 2020, Stockholm
DAY 1 - Monday March 16, 2020
Registration and Refreshments
Opening Remarks and an Update on Genomic Medicine Sweden from the Chair:

   Prof Richard Rosenquist Brandell, Professor of Clinical Genetics, Department of Molecular Medicine and Surgery, Karolinska Institutet, Senior Physician, Clinical Genetics, Karolinska University Hospital, & Director, Genomic Medicine Sweden

Precision Medicine: National Initiatives and Regulation: Where We Are and Next Steps

A panel of expert speakers from across the Nordic region will outline current policy and regulations governing precision medicine, and the initiatives being implemented to further advance its implementation, in their specific countries. A panel discussion will then explore some of the following issues:

  • How can flexibility be built into policy development to enable regulatory frameworks to adapt and innovate as research and technology progresses?
  • To what extent can, or should, national regulations be harmonised, or common European policies adopted to facilitate and advance precision medicine?
  • Assessing where time, energy and investment should be best focused in order to implement precision medicine into the clinical setting

   Dr Päivi Sillanaukee, Director General, Ministry of Social Affairs and Health, Finland

   Dr Grethe S. Foss, Project Leader Personalised Medicine & Senior Adviser, The Norwegian Directorate of Health

   Dr Kári Stefánsson,  President, Chairman, CEO and Co-Founder, deCODE Genetics

   Peter Johansen, Special Advisor, Healthcare Team, Danish National Genome Center

Networking Lunch

Patient’s Perspective: Patients as a Driving-Force to Advance Precision Medicine

Panel session Led by Apotekarsocieteten: The Development and Manufacture of More Precise Drug Delivery Systems, Drug Products & Drug Formulations

This session, led by Apotekarsocieteten, the Swedish Pharmaceutical Society, will comprise of a series of short presentations on drug development for precision medicine, followed by a panel debate.

   Chair: Dr Agneta Larhed, Senior Consultant, RegSmart Life Science & Drug Formulation Section, Apotekarsocieteten

Individualized Manufacturing and GMP - How Does It Work?

   Emil Smal, Pharmaceutical Inspector, Medical Products Agency, Uppsala

Precision Medicine in Immuno-Oncology

   Sara Mangso, Associate Senior Lecturer, Uppsala University

A Flexible, Connected Approach to Individual Dosage Management

   Martin Olovsson, CEO, OnDosis, Gothenburg

Panel Debate: Opportunities and Challenges for Precise Drug Substances & Drug Products

   Emil Schwan, Pharmaceutical Inspector, Medical Products Agency, Uppsala

   Sara Mangsbo, Associate Senior Lecturer, Uppsala University

   Martin Olovsson, CEO, OnDosis, Gothenburg

   Per Wessman, Head of Formulation, RISE Research Institutes of Sweden

Refreshments and Networking
Delegates move to their chosen break-out session
Interactive Break-Out Sessions

These focused, interactive sessions give you the opportunity to discuss a key topic of interest to you in a more participative format. Each session will be led by a facilitator who will lead the discussion and encourage maximum debate and sharing of ideas.

A. Intelligent Health: Unlocking the Potential in Life Course Digital Health Data

  Prof Carsten Obel, Professor in General Medicine, Data, Innovation & Technology Public Health Lab, Department of Public Health, Aarhus University

B. Proving the Financial Business Case for Precision Medicine
C. Getting Meaningful Outcomes from “Big Data”

   Merike Leego, Innovation Manager, EIT Health Scandinavia

D. Successfully Implementing Precision Medicine Research into Clinical Practice

   Bogi Eliasen, Associated Partner, Health & Medicine, Genetics & Genomics, Public Policy, Copenhagen Institute for Future Studies

E. Leveraging Public-Private Partnerships & Funding Mechanisms to Advance the Delivery of Precision Medicine

F. Advances in Biomarker Development & Validation for Enhanced Clinical Insights 

G. Effectively Using Digital Biomarkers for Advanced Diagnostics and Personalised Healthcare
H. Identifying & Overcoming Potential Drug Resistance to Advance Precision Medicine
Reconvene in main conference room
Emerging Innovations & Technology to Advance Precision Medicine

This new technology “pitch” session will give you the opportunity to hear first-hand the innovative, disruptive, and emerging technologies that can help advance precision medicine, through managing the huge volumes of complex, confidential healthcare data; to developing complex diagnostics; to new AI and e-health technologies.

Close of conference followed by Complimentary Networking Drinks Reception
DAY 2 - Tuesday March 17, 2020
Welcome Refreshments and Networking
Opening Remarks from the Chair
The Economics of Precision Medicine: Establishing Value and Proving the Financial Business Case for Precision Medicine
  • Exploring the perception of “value” and the key criteria on which investment and funding decisions are made:
    • to what extent can evidence-based testing and technologies facilitate these decisions?
  • Examining how the disease and drug classification and reimbursement system could be changed to enable a broader, biological approach: how does this differ across different European countries?
  • Developing effective reimbursement mechanisms to meet the requirements of the payer and “justify” precision medicine
  • Finding an effective balance between value economics and optimum patient care
Determining Appropriate Governance to Manage the Legal & Ethical Considerations of Sharing and Using Biological & Healthcare Data
  • Determining the extent to which specific provision for scientific research within General Data Protection Regulation (GDPR) differs across European countries:
    • what frameworks, principles and norms have so far been developed to ensure an ethical approach to data sharing in health research?
  • Managing the balance between patient privacy rights and the benefits of data-sharing
    • understanding patients’ expectations of research and the societal benefits and value from it 
    • how do we generate and maintain patient trust with regards to their personal information?
  • Assessing the impact of AI and digital healthcare on data governance requirements

   Heidi Beate Bentzen, Doctoral Research Fellow, The Centre for Medical Ethics, Faculty of Medicine and Faculty of Law, University of Oslo

Morning Refreshments & Networking
The programme will now split into 2 tracks. Delegates are invited to choose the track they would like to attend.
Data - Leveraging the Power of “Big Data” to Realise its Full Potential for Delivering Precision Medicine
One of the key challenges for the advancement of precision medicine is transforming the huge amount of genetic data being generated into a tool to improve disease classification, “unlock” diagnoses and identify new treatment options. As well as the significant privacy and trust issues to be overcome, there are a number of technical obstacles. Health data is not easily accessible by researchers, patients and doctors when and how they need it in order to deliver better outcomes; instead it is “siloed”; held in divergent systems in numerous different formats in huge unmanageable quantities. This session will explore new ways of managing, integrating and analysing biological and healthcare information to maximise its potential value.
Strategies for Enhancing the Quality of Data Available & Optimise Its Use
  • Examining the key issues currently affecting data availability, affordability and quality 
  • Assessing what needs to be done to monitor this and ensure data gathered is as usable as possible:
    • benchmarking
    • harmonisation
    • standardisation
  • Identifying which technologies can facilitate the flow of health data

   Dr Sharmini Alagaratnam, Principal Researcher, Precision Medicine Research Programme, DNV GL

Unlocking the True Potential of Multi-Omics Data Through Integrated Bio-Informatics
  • Identifying the key challenges in multi-omics data utilisation and possible solutions
  • Assembling the right “toolbox” for optimum data integration and analysis:
    • developing robust and transparent bioinformatic pipelines to provide timely and useful clinical information 
    • using new data analysis tools to gain better insights from the information available 
    • techniques for reporting the findings in a coherent and useful way  
  • Exploring new methods for integrating genetic data from different sources to find the meaningful overlap:
    • selecting the most relevant variables from different -omics datasets and samples
    • techniques for extracting common information from different datasets for the same patients and classifying patients
  • Successfully translating multi-omics data into clinically actionable biomarkers

   Dr Antonio Andreu, Scientific Director, EATRIS

Effectively Integrating Patient Data into the Healthcare System to Optimise Its Use
  • Exploring how the increasing volume of behavioural and lifestyle data can be integrated appropriately with clinical data:
    • effectively integrating patient-led self-care with physician-led primary care decision support tools
  • Embedding information gathering and reporting into the healthcare system to facilitate the development of a “learning health system”; a feedback loop to achieve increased patient engagement
Panel Q & A Discussion
Networking Lunch
Advancing Precision Medicine Through Multi-Omics Strategies

Deriving molecular signatures from multi-omics data has the potential to more accurately define disease, improve patient stratification and predict likely drug or therapy response. There have been many advances in the use of multi-omics data, however some omics are more developed than others. This session will explore what is being achieved with different -omics and how ready they are for clinical use.

A Multi-Omics Diagnostic Approach in a Rare Inborn Error of Metabolism

    Prof Dr Rikke Olsen, Associate Professor, The Research Unit for Molecular Medicine (MMF), Department of Clinical Medicine (DCM), Aarhus University Hospital

Implementing Pharmacogenomics into Clinical Practice

    Prof Dr Matthias Schwab, Head of the Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and Department of Clinical Pharmacology, University Hospital, Tübingen

Metabolomics: Metabolic Profiling as An Early Diagnosis Tool for Precision Medicine

   Prof Dr Vidya Velagapudi, Head of the Metabolomics Unit, Institute for Molecular Medicine Finland (FIMM) & Adjunct Professor, Department of Biosciences, University of Helsinki

Using Proteomics & Integrated Proteogenomics to Better Understand Molecular Profiles and Improve Disease Detection, Diagnosis & Prevention
Better Understanding Microbiomics to Advance Precision Medicine
Networking Lunch
The afternoon session will continue in 2 tracks. Delegates are again invited to choose which of the tracks they would like to attend
Diagnostics & Biomarker Development
Exploring the Effective Development and Integration of Digital Biomarkers
  • Exploring the latest innovations in mobile, smart, cloud and self-diagnostic technologies for obtaining patient data and insights for use as digital biomarkers
  • Identifying the challenges to be overcome in using digital biomarkers and possible solutions:
    • reliability of technology and results
    • standardisation of results from patient technology and in a clinical setting
    • data privacy issues
  • Successfully leveraging the information generated to track trends and patterns for individuals and populations:
    • examining what tools are needed to effectively integrate e-health technology into clinical practice
    • assessing the implications for healthcare systems of patient self-management technologies and increased patient empowerment
  • Demonstrating the use of health-tech and patient-driven technology as diagnostic tools in practice

   Prof Tomi Mäkelä, Director, Helsinki Institute of Life Science & Executive Officer, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki

Examining the Development of Pan-Tumour Molecular Profiling to Provide Better Clinical Insights and Enable Agnostic Drug Development
  • Examining the progress made so far in work being done to re-characterise cancers as mutation-based rather than organ-based
  • Advancing molecular tumour boards to advance precision medicine – identifying key information requirements
Developing Innovative Biomarkers for a Personalized Medicine Approach
Afternoon Refreshments & Networking
Moving Beyond Genomics – The Development of Functional or Systems Precision Medicine
Genomic profiling is driving the development of precision medicine, particularly with regards to oncology. However, a key challenge is being able to match effective drugs to genomic profiles, which are often complex and unique to each patient. Furthermore, even when it is possible to target certain genes, it is not always clear which one should be prioritised, or which drug would be most effective. This session will explore how the development and application of functional analysis could be used as a precision medicine tool alongside genomic-focused approaches to improve targeted drug development and accelerate clinical implementation.
Examining how Functional Assays Can Be Used as Diagnostic Tools to Facilitate the Development of Predictive Biomarkers for Personalised Drug Development
  • Optimising national quality registers to create a decision-making support framework based on genomic data
  • Integrating technology with existing healthcare databases to give better patient knowledge and insight
  • Exploring how we can turn broad genomic profiling into information that can be used quickly and easily for patients’ benefit in clinics

  Prof Dr Krister Wennerberg, Professor, Biotech Research & Innovation Centre (BRIC), University of Copenhagen

Integrating Multi-Omic and Functional Drug Testing for Precision Medicine to Advance Effective Drug Development & Re-Purposing

   Dr Päivi Östling, Associate Professor & Co-Principal Investigator, Kallioniemi Research Group, SciLifeLab

Recent Innovations in Functional Analysis & Diagnostics
Q & A Discussion
Afternoon Refreshments & Networking
A Final Plenary Session will Conclude the Afternoon
Making It A Reality: Effectively Implementing Precision Medicine Into Clinical Practice

This final, but perhaps most important, session will bring together the R&D advances and different approaches being taken to develop precision medicine that have been discussed throughout the day and explore how they can best be translated into clinical practice. It will discuss the challenges currently hindering this implementation and explore where and how changes need to be made in order to create better flexibility, foster innovation, and deliver precision medicine in reality.

Data-Driven Molecular Precision Medicine

   Professor Dr Olli-Pekka Kallioniemi, Professor of Molecular Precision Medicine, Karolinska Institutet & Director, Science for Life Laboratory

Precision Medicine: Getting to the Heart of the Matter

   Dr David O. Arnar, Chief of Cardiology, Landspitali - The National University Hospital, Iceland

Examining How Healthcare Systems Need to Adapt in Order to Truly Deliver Precision Medicine
  • Assessing the infrastructure, data and technology changes required to current healthcare systems in order to deliver a precision medicine approach
  • Research / Clinic interaction: Exploring how to translate broad genomic and multi-omic profiling data into actionable insights that can be used in clinics
  • Discovering innovative ways of reorganising healthcare systems with limited resources
  • Assessing the effectiveness of clinical trials and how they can facilitate precision medicine in practice
Developing and Implementing Precision Medicine & Digital Health Communication & Training Programmes for Healthcare Professionals (HCPs)
  • Assessing how the role of HCPs will change in future and how they will need to adapt to deliver  healthcare, including digital health and precision medicine 
  • Effectively managing increasing patient empowerment
  • Communicating and convincing HCPs of the validity and potential of new personalised treatments and therapies
  • Training HCPs to analyse and effectively use the data available to them
Panel Q&A Discussion
Closing Remarks from the Chair and Close of Conference
With Special Thanks to Our Sponsors, Exhibitors and Partners
© Precision Medicine Forum